Our current results show that expression of PTRF in prostate cancer cells further reduces their angiogenic and lymphangiogenic potential by inhibiting essential steps of these processes such as blood and lymphatic EC proliferation, migration, and tube formation. The gene discussed is CAVIN1; the disease is prostate carcinoma.